EW Edwards LifesciencescompanySEC Filings & Insider Trading Activity 2026
Latest Edwards Lifesciences (EW) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 25, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on April 23, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Edwards Lifesciences (EW) (SEC CIK 1099800), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Management Discussion & Analysis
- • Revenue $6.07B, up $628.1M (+11.5% YoY); TMTT best-performing segment +56.4% to $550.6M; Surgical weakest at +4.9% to $1.03B
- • Gross profit as % of net sales decreased due to higher operational expenses; litigation expenses surged to $325.4M in 2025 vs $40.4M in 2024; effective tax rate 17.0% vs 9.8%
Business Overview
- • Structural heart pure-play: TAVR, TMTT, and Surgical segments targeting aortic, mitral, tricuspid, and pulmonic valve disease
- • TMTT fastest-growing segment: revenue share expanded to 9% in FY2025 vs 7% in FY2024 and 4% in FY2023
Risk Factors
- • Section 232 investigation by U.S. Dept. of Commerce into medical device imports could impose tariffs, raising manufacturing costs and disrupting Edwards' supply chain
- • EU MDR compliance risk: unresolved EU-Switzerland Mutual Recognition Agreement may block Edwards from placing devices on EU market via Swiss operations
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Management Discussion & Analysis
- • Revenue $1.55B for Q3 2025, up 14.7% YoY from $1.35B; nine-month revenue $4.50B, up 11.0% YoY from $4.05B
- • Gross profit rose YoY but gross margin declined due to forex and higher expenses; effective tax rate 16.1% vs 9.2% YoY for nine months
Risk Factors
- • No material changes to Risk Factors compared to 2024 10-K
- • Continued exposure to product liability risks in medical device industry
Annual Reports Archive10-K
AI-powered analysis of Edwards Lifesciences (EW) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Edwards Lifesciences (EW) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | — | $6.0B | $5.4B | $6.1B |
| Gross Profit | — | $4.6B | $4.3B | $4.7B |
| Operating Income | $1.7B | $1.5B | $1.4B | $1.3B |
| Net Income | — | $1.4B | $4.2B | $1.1B |
| Gross Margin | — | 77.0% | 79.5% | 78.0% |
| Op. Margin | — | 25.5% | 25.3% | 20.8% |
| Net Margin | — | 23.4% | 76.7% | 17.7% |
| Balance Sheet | ||||
| Total Assets | $8.3B | $9.4B | $13.1B | $13.7B |
| Equity | — | $6.7B | $10.0B | $10.3B |
| ROE | — | 21.1% | 41.8% | 10.4% |
Source: XBRL financial data from Edwards Lifesciences (EW) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 23, 2026 | — | — | — |
10-K | Feb 25, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 10, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 6, 2025 | Jun 30, 2025 | — | |
10-Q | May 6, 2025 | Mar 31, 2025 | — | |
10-K | Feb 28, 2025 | Dec 31, 2024 | Analysis | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Jul 31, 2024 | Jun 30, 2024 | — | |
10-Q | Apr 29, 2024 | Mar 31, 2024 | — | |
10-K | Feb 12, 2024 | Dec 31, 2023 | — | |
10-Q | Oct 27, 2023 | Sep 30, 2023 | — | |
10-Q | Jul 28, 2023 | Jun 30, 2023 | — | |
10-Q | Apr 28, 2023 | Mar 31, 2023 | — | |
10-K | Feb 13, 2023 | Dec 31, 2022 | — | |
10-Q | Oct 28, 2022 | Sep 30, 2022 | — | |
10-Q | Jul 29, 2022 | Jun 30, 2022 | — | |
10-Q | Apr 28, 2022 | Mar 31, 2022 | — | |
10-K | Feb 14, 2022 | Dec 31, 2021 | — | |
10-Q | Oct 29, 2021 | Sep 30, 2021 | — | |
10-Q | Jul 30, 2021 | Jun 30, 2021 | — | |
10-Q | Apr 28, 2021 | Mar 31, 2021 | — | |
10-K | Feb 12, 2021 | Dec 31, 2020 | — | |
10-Q | Oct 26, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest EW SEC filings in 2026?
Edwards Lifesciences (EW) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on April 23, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did EW file its most recent 10-K annual report?
Edwards Lifesciences (EW) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view EW 10-Q quarterly reports?
Edwards Lifesciences (EW)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every EW 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has EW filed recently?
Edwards Lifesciences (EW)'s most recent 8-K was filed on April 23, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find EW insider trading activity (Form 4)?
SignalX aggregates every EW Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does EW file with the SEC?
Edwards Lifesciences (EW) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new EW filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Edwards Lifesciences (EW).
What is EW's SEC CIK number?
Edwards Lifesciences (EW)'s SEC CIK (Central Index Key) number is 1099800. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1099800 to look up all EW filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find EW return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Edwards Lifesciences (EW) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Edwards Lifesciences SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 34+ filings.